Councils - Basic Science and Translational Research



Scientific Council on Basic Science & Translational Research



NOT A COUNCIL MEMBER?

Council membership is open to all ISHLT members. Joining is easy. Simply login to the ISHLT Members Only Website where you can update your membership profile and join any of the 12 Scientific Councils.



PAST COUNCIL MEETING:
Friday, April 7, 2017, 11:30 AM - 1:30 PM
in  Seaport F-H of the Manchester Grand Hyatt Hotel, San Diego, CA, USA, during the ISHLT 37th Annual Meeting and Scientific Sessions



BSTR JOURNAL WATCH:

http://ishlt.org/councils/brightLights.asp



LINKS NEWSLETTER:

Issues focusing on Basic Science:

December 2016
August 2016
June 2015: BSTR Council Year in Review
December 2014
November 2013
July 2013
May 2013: BSTR Council Year in Review
August 2012
August 2011 (PDF)




INTERESTED IN MENTORSHIP?

Visit the Junior Faculty and Trainee Council page for information on the ISHLT Mentorship Program

COUNCIL LEADERSHIP OPERATING BOARD
(Parentheses after name indicates year rotating off Board)


COUNCIL CHAIR:

Edward Cantu, III, MD (2021)
Hospital of the University of Pennsylvania
Philadelphia, PA, USA

Edward Cantu, MD MSCE is the Director of Lung Transplant Research, Director of Ex Vivo Lung Perfusion and Associate Director of Lung Transplantation at the University of Pennsylvania. His laboratory is focused on acute lung injury and primary graft dysfunction after lung transplantation with emphasis on prediction, mechanism and therapeutic discovery. He obtained his MD from Columbia University College of Physicians and Surgeons in 2000. Residency and Cardiothoracic fellowship training was obtained at Duke University from 2000-2010. In 2010, he was recruited to Penn as an Assistant Professor of Surgery. He completed a Masters in Clinical Epidemiology with emphasis in human genetics in 2015 from Penn. Dr. Cantu has received numerous awards for his research in the field of transplantation including the STS J. Maxwell Chamberlain Award in 2003, the ASTS Thoracic Award in 2007, and the Thoracic Surgery Foundation for Research and Education Award in 2014. Dr. Cantu is currently actively funded by the NIH, Robert Wood Johnson Foundation, the STS, and the Philadelphia Antiques Show.



COUNCIL VICE CHAIR:

Joshua M Diamond, MD (2023)
University of Pennsylvania
Philadelphia, PA, USA

Joshua M. Diamond, M.D., M.S.C.E is currently the Associate Medical Director of the University of Pennsylvania Lung Transplant Program in Philadelphia, PA. His research is focused on translational studies of the risks, pathogenesis, and outcomes of primary graft dysfunction (PGD) and the evaluation of potential therapies for PGD in the lung transplant population. He graduated from the University of Rochester School of Medicine in 2004 and completed his internal medicine residency in 2007 and pulmonary/critical care fellowship in 2011 at the University of Pennsylvania. He received a Master’s Degree in clinical epidemiology from the University of Pennsylvania in 2001, with a thesis focused on innate immunity in primary graft dysfunction after lung transplantation. He received the American Thoracic Society Assembly on Clinical Problems Early Career Achievement Award in 2015. In addition to his transplant roles, he is also the Director of the Clinical Research Track for the Penn pulmonary fellowship program.



COUNCIL PAST CHAIR:

Sonja Schrepfer, MD, PhD (2019)
University of California San Francisco (UCSF)
Department of Surgery
Transplant and Stem Cell Immunobiology Lab (TSI)
San Francisco, CA, USA and
University Heart Center Hamburg
Transplant and Stem Cell Immunobiology Lab (TSI)
Hamburg, Germany

Sonja Schepfer, MD, PhD is Director of the Transplant and Stem Cell Immunobiology (TSI)-Lab at the University Heart Center in Hamburg, Germany. She is also a Visiting professor of CT Surgery at the Stanford University, School of Medicine. Her laboratory investigates experimental cardiac and lung transplantation, myocardial restoration, and vascular biology and her specific area of interest is translational research of stem cell immunobiology and solid organ transplantation. She graduated in Medicine in 2002 at the Universities Wuerzburg and Munich (Germany) and received her PhD in Immunology in 2007. She completed her postdoctoral fellowship in CT Surgery at Stanford University and started the CT Surgery Transplant Immunobiology group in 2007. Dr. Schrepfer received numerous awards for her research in the field of transplant and stem cell immunology, including the "Norman E Shumway Career Development Award" in 2010 from the ISHLT, the "Rudolf Pichlmayr Award" in 2007 from the German Transplant Society,and the "DFG Heisenberg W3-Professorship" in 2009; more information is available at http://www.tsi-lab.de/" target="_blank">www.TSI-lab.de.



BOARD OF DIRECTORS LIAISON:

Stephan M. Ensminger, MD, DPhil (2018)
Heart and Diabetes Center NRW
Ruhr-University Bochum
Bad Oeynhausen, GERMANY

Stephan Ensminger, M.D., D.Phil. is a Professor of Cardiothoracic Surgery and one of the Deputy Heads of the Department of Thoracic and Cardiovascular Surgery at the Heart and Diabetes Center NRW, Ruhr University Bochum at Bad Oeynhausen, Germany. Dr. Ensminger graduated from the University of Würzburg Medical School in 1996, followed by an internship in Cardiothoracic Surgery at the University of Tübingen, Germany and a D.Phil. in Transplantation Immunology at the Nuffield Department of Surgery at the University of Oxford, U.K. under the supervision of Prof. Kathryn Wood in 2000. He received his cardiothoracic surgery training at the University of Erlangen-Nürnberg, Germany, where he was appointed as a Professor of Experimental Cardiac Surgery in 2008. His particular interests are Transplantation Immunology with the main focus on the immunobiology of cardiac allograft vasculopathy (CAV) and minimally invasive cardiac surgery with the emphasis on catheter based valve therapies (TAVR). He is currently a member of the executive board of the German Society of Thoracic and Cardiovascular Surgery and the German Aortic Valve Registry (GARY).



EDUCATION WORKFORCE LEADER:

Mary Porteous, MD (2019)
Hospital of the University of Pennsylvania
Philadelphia, PA, USA

Mary Porteous, MD MSCE is currently an Assistant Professor of Medicine at the University of Pennsylvania. Her research is focused on evaluating the risks, pathogenesis, and outcomes of primary graft dysfunction after lung transplant as well as clinical progression of interstitial lung disease prior to transplantation. She graduated from the University of Maryland School of Medicine in 2008 and completed her internal medicine residency in 2011 and pulmonary and critical care fellowship in 2015 at the University of Pennsylvania. She earned a Master's Degree in clinical epidemiology from the University of Pennsylvania in 2015 with a thesis focused on the impact of diastolic dysfunction on primary graft dysfunction after lung transplantation.



I2C2 WORKFORCE LEADER:

Ciara M. Shaver, MD, PhD (2020)
Vanderbilt University Medical Center
Nashville, TN, USA

Ciara Shaver, MD, PhD is a transplant pulmonologist at Vanderbilt Medical Center. Her clinical work is dedicated to the care of lung transplant recipients. Her research program is focused on understanding the molecular pathogenesis of primary graft dysfunction, using a combination of basic, translational, and clinical approaches. Dr. Shaver received her undergraduate degree from Rice University, then completed her MD/PhD training at Northwestern University Feinberg School of Medicine in 2007.

She then moved to Vanderbilt for residency in internal medicine followed by a pulmonary and critical care fellowship. She is currently funded by the NIH and a Parker B. Francis Fellowship in Pulmonary Research.





STANDARDS AND GUIDELINES COMMITTEE WORKFORCE LEADER:

Keshava Rajagopal, MD, PhD (2018)
University of Texas
Houston, TX, USA

Keshava Rajagopal, MD PhD, is an attending cardiac surgeon and Assistant Professor of Cardiovascular/Thoracic Surgery at the University of Texas-Houston and Memorial Hermann-Texas Medical Center, and Surgical Director of Lung Transplantation. He received his undergraduate education (BS, Chemistry) at the University of Pittsburgh, followed by his MD and PhD (Immunology; laboratory of Jeffrey Bluestone) in the Medical Scientist Training Program at The University of Chicago. He undertook training in general surgery, part of which included a 2 year postdoctoral fellowship studying cardiovascular G protein coupled receptor signal transduction with Robert Lefkowitz, at Duke University Medical Center. Subsequently, he trained in cardiothoracic surgery at Duke. Currently, his clinical practice is the surgical management of end-stage heart and lung disease, while his scientific research efforts are focused on studying cardiac mechanotransduction and cardiovascular bioengineering.



OTHER REPRESENTATIVES:

SENIOR ADVISORS:

Doris A. Taylor, PhD
University of Minnesota
Minneapolis, Minnesota, USA

Doris A. Taylor, PhD, FAHA, FACC, is Founder, President, and CEO of Stem Cell Security, a cell banking and data management company in Houston, Texas. A pioneer in cardiovascular cell therapy and regenerative medicine research, Dr. Taylor has committed her entire career to moving innovative therapies from bench to bedside. Her mechanistic insights and effective approaches to cardiac repair and replacement are well established and include a number of firsts. She holds several invention disclosures, patent applications, and patents, and is the founder of multiple companies dedicated to cardiovascular repair technologies. She has published extensively, authoring or co-authoring more than 125 scientific publications, and holds many honors, including appointments as a Fellow of the American Heart Association, the American College of Cardiology, and the Council on Functional Genomics and Translational Biology, among others. She has been recognized by the AHA for Top 10 Research Advances and was awarded an honorary Doctorate Science degree by her alma mater, Mississippi University for Women in 2015. Dr. Taylor appears frequently as an expert on stem cell therapy and cardiac repair in the media as well as in the scientific arena. Her work has been recognized and featured by 60 Minutes, CNN, The New York Times, The Wall Street Journal, BBC News Health, the Associated Press, National Public Radio, and numerous other worldwide media outlets. She holds a B.S. from Mississippi University for Women in Biology and Physical Sciences in 1977 and a PhD in Pharmacology from the University of Texas Southwestern Medical Center, Dallas, Texas in 1987.



Jeffrey L. Platt, MD
University of Michigan
Ann Arbor, Michigan, USA

Jeffrey L. Platt, M.D. directs the Transplantation Biology Program and serves as Professor of Surgery, and Professor of Microbiology and Immunology at the University of Michigan.  He investigates how T cells and B cells and their products interact with tissues to cause disease and to induce protection against further injury, how novel approaches might be used to replace organ function and restore immunological fitness and how fusion of one cell with another impacts on genomic integrity and cellular function.  Dr. Platt is trained in Pediatrics (Childrens Hospital of LA) and nephrology (Univ Minnesota) and is a member of long standing of the ASN, AHA, the Association of American Physicians, IOM and the ISHLT.


ISHLT LINKS NEWSLETTER LIAISON:

Howard J. Eisen, MD, FAHA, FACC, FACP (2020)
Drexel University College of Medicine and Hahnemann University Hospital
Philadelphia, PA, USA





LIAISONS TO OTHER COUNCILS:

HFTX COUNCIL LIAISON:

Pradeep P.A. Mammen, MD, FACC, FAHA (2020)
UT Southwestern Medical Center
Dallas, Texas, USA

Bio coming soon...





ID COUNCIL LIAISON:

Orla Morrissey, MD (2020)
Alfred Health
Melbourne, AUSTRALIA

Bio coming soon...





JUNIOR FACULTY & TRAINEE COUNCIL LIAISON:

Simon Pecha, MD (2019)
University Hospital Hamburg
Hamburg, GERMANY

Simon Pecha, MD, is a Cardiac Surgeon at University Heart Center Hamburg, Germany and leads a Research group for Myocardial Tissue Engineering at Cardiovascular Research Center Hamburg. He obtained his MD from University of Tuebingen and received his training in Cardiovascular Surgery at University Heart Center Hamburg. His research is related to Cardiac Regeneration with a focus on Myocardial tissue engineering from human induced pluripotent stem cells. Dr. Pecha received several awards for his research including the Philip K. Caves Award in 2015 from the ISHLT and the Dr. Martini Price 2017 from the Dr. Martini Foundation.



MCS COUNCIL LIAISON:

J. Michael DiMaio, MD (2020)
Baylor University Medical Center
Dallas, TX, USA

Bio coming soon...





NHSAH COUNCIL LIAISON:

Monica Horn, RN, CCRN, CCTC (2020)
Children’s Hospital Los Angeles
Los Angeles, CA, USA

Monica Horn is a Heart Transplant/VAD/PH Coordinator II, Lead at Children’s Hospital Los Angeles. Previously a pediatric critical care RN, she became a cardiothoracic transplant coordinator in 1994, working with lung/heart-lung/lobar lung transplant,  heart transplant, pulmonary hypertension and ventricular assist device patients while participating in multiple research publications regarding these populations throughout this time. Recent interests have included multidisciplinary collaboration in care of pediatric ventricular assist device patients and patients referred for heart transplantation who have had multiple previous palliative congenital heart surgeries.



PATH COUNCIL LIAISON:

Annalisa Angelini, MD (2020)
University of Padua
Padova, ITALY

Bio coming soon...





PH COUNCIL LIAISON:

Aaron B Waxman, MD, PhD (2020)
Brigham & Women's Hospital
Boston, MA, USA

Bio coming soon...





PULM TX COUNCIL LIAISON:

Pablo G. Sanchez, MD, PhD (2020)
University of Pittsburgh
Pittsburgh, PA, USA

Pablo G Sanchez, MD PhD, is a Lung Transplant Surgeon. He is the  Associate Director of Lung Transplant and the Adult ECLS program and the Director of Ex vivo Lung Perfusion and Lung Transplant Research at the University of Pittsbugh. He obtained his MD from the University of Cordoba, Argentina in 1999. Residency and Thoracic Surgery fellowship was obtained at the Santa Casa de Misericordia, Porto Alegre, Brazil. He also completed a research fellowship at the University of Pennsylvania, and a Post Doc fellowship at the University of Maryland. He is a national co-investigator for the NOVEL trial, evaluating the use of ex vivo perfusion to increase lung donor use. He received the F. Griffith Pearson Fellowship from The American Association for Thoracic Surgery. He has also received funding from the Maryland Stem Cell Research Foundation, the ISHLT research fellowship award and the University of Maryland and Living Legacy Foundation Transplantation Grant Program Award.



COUNCIL LEADERSHIP OPERATING BOARD
(Parentheses after name indicates year rotating off Board)


COUNCIL CHAIR:

Edward Cantu, III, MD (2021)
Hospital of the University of Pennsylvania
Philadelphia, PA, USA

Edward Cantu, MD MSCE is the Director of Lung Transplant Research, Director of Ex Vivo Lung Perfusion and Associate Director of Lung Transplantation at the University of Pennsylvania. His laboratory is focused on acute lung injury and primary graft dysfunction after lung transplantation with emphasis on prediction, mechanism and therapeutic discovery. He obtained his MD from Columbia University College of Physicians and Surgeons in 2000. Residency and Cardiothoracic fellowship training was obtained at Duke University from 2000-2010. In 2010, he was recruited to Penn as an Assistant Professor of Surgery. He completed a Masters in Clinical Epidemiology with emphasis in human genetics in 2015 from Penn. Dr. Cantu has received numerous awards for his research in the field of transplantation including the STS J. Maxwell Chamberlain Award in 2003, the ASTS Thoracic Award in 2007, and the Thoracic Surgery Foundation for Research and Education Award in 2014. Dr. Cantu is currently actively funded by the NIH, Robert Wood Johnson Foundation, the STS, and the Philadelphia Antiques Show.


COUNCIL VICE CHAIR:

Joshua M Diamond, MD (2023)
University of Pennsylvania
Philadelphia, PA, USA

Joshua M. Diamond, M.D., M.S.C.E is currently the Associate Medical Director of the University of Pennsylvania Lung Transplant Program in Philadelphia, PA. His research is focused on translational studies of the risks, pathogenesis, and outcomes of primary graft dysfunction (PGD) and the evaluation of potential therapies for PGD in the lung transplant population. He graduated from the University of Rochester School of Medicine in 2004 and completed his internal medicine residency in 2007 and pulmonary/critical care fellowship in 2011 at the University of Pennsylvania. He received a Master’s Degree in clinical epidemiology from the University of Pennsylvania in 2001, with a thesis focused on innate immunity in primary graft dysfunction after lung transplantation. He received the American Thoracic Society Assembly on Clinical Problems Early Career Achievement Award in 2015. In addition to his transplant roles, he is also the Director of the Clinical Research Track for the Penn pulmonary fellowship program.


COUNCIL PAST CHAIR:

Sonja Schrepfer, MD, PhD (2019)
University of California San Francisco (UCSF)
Department of Surgery
Transplant and Stem Cell Immunobiology Lab (TSI)
San Francisco, CA, USA and
University Heart Center Hamburg
Transplant and Stem Cell Immunobiology Lab (TSI)
Hamburg, Germany

Sonja Schepfer, MD, PhD is Director of the Transplant and Stem Cell Immunobiology (TSI)-Lab at the University Heart Center in Hamburg, Germany. She is also a Visiting professor of CT Surgery at the Stanford University, School of Medicine. Her laboratory investigates experimental cardiac and lung transplantation, myocardial restoration, and vascular biology and her specific area of interest is translational research of stem cell immunobiology and solid organ transplantation. She graduated in Medicine in 2002 at the Universities Wuerzburg and Munich (Germany) and received her PhD in Immunology in 2007. She completed her postdoctoral fellowship in CT Surgery at Stanford University and started the CT Surgery Transplant Immunobiology group in 2007. Dr. Schrepfer received numerous awards for her research in the field of transplant and stem cell immunology, including the "Norman E Shumway Career Development Award" in 2010 from the ISHLT, the "Rudolf Pichlmayr Award" in 2007 from the German Transplant Society,and the "DFG Heisenberg W3-Professorship" in 2009; more information is available at http://www.tsi-lab.de/" target="_blank">www.TSI-lab.de.


BOARD OF DIRECTORS LIAISON:

Stephan M. Ensminger, MD, DPhil (2018)
Heart and Diabetes Center NRW
Ruhr-University Bochum
Bad Oeynhausen, GERMANY

Stephan Ensminger, M.D., D.Phil. is a Professor of Cardiothoracic Surgery and one of the Deputy Heads of the Department of Thoracic and Cardiovascular Surgery at the Heart and Diabetes Center NRW, Ruhr University Bochum at Bad Oeynhausen, Germany. Dr. Ensminger graduated from the University of Würzburg Medical School in 1996, followed by an internship in Cardiothoracic Surgery at the University of Tübingen, Germany and a D.Phil. in Transplantation Immunology at the Nuffield Department of Surgery at the University of Oxford, U.K. under the supervision of Prof. Kathryn Wood in 2000. He received his cardiothoracic surgery training at the University of Erlangen-Nürnberg, Germany, where he was appointed as a Professor of Experimental Cardiac Surgery in 2008. His particular interests are Transplantation Immunology with the main focus on the immunobiology of cardiac allograft vasculopathy (CAV) and minimally invasive cardiac surgery with the emphasis on catheter based valve therapies (TAVR). He is currently a member of the executive board of the German Society of Thoracic and Cardiovascular Surgery and the German Aortic Valve Registry (GARY).


EDUCATION WORKFORCE LEADER:

Mary Porteous, MD (2019)
Hospital of the University of Pennsylvania
Philadelphia, PA, USA

Mary Porteous, MD MSCE is currently an Assistant Professor of Medicine at the University of Pennsylvania. Her research is focused on evaluating the risks, pathogenesis, and outcomes of primary graft dysfunction after lung transplant as well as clinical progression of interstitial lung disease prior to transplantation. She graduated from the University of Maryland School of Medicine in 2008 and completed her internal medicine residency in 2011 and pulmonary and critical care fellowship in 2015 at the University of Pennsylvania. She earned a Master's Degree in clinical epidemiology from the University of Pennsylvania in 2015 with a thesis focused on the impact of diastolic dysfunction on primary graft dysfunction after lung transplantation.


I2C2 WORKFORCE LEADER:

Ciara M. Shaver, MD, PhD (2020)
Vanderbilt University Medical Center
Nashville, TN, USA

Ciara Shaver, MD, PhD is a transplant pulmonologist at Vanderbilt Medical Center. Her clinical work is dedicated to the care of lung transplant recipients. Her research program is focused on understanding the molecular pathogenesis of primary graft dysfunction, using a combination of basic, translational, and clinical approaches. Dr. Shaver received her undergraduate degree from Rice University, then completed her MD/PhD training at Northwestern University Feinberg School of Medicine in 2007.

She then moved to Vanderbilt for residency in internal medicine followed by a pulmonary and critical care fellowship. She is currently funded by the NIH and a Parker B. Francis Fellowship in Pulmonary Research.



STANDARDS AND GUIDELINES COMMITTEE WORKFORCE LEADER:

Keshava Rajagopal, MD, PhD (2018)
University of Texas
Houston, TX, USA

Keshava Rajagopal, MD PhD, is an attending cardiac surgeon and Assistant Professor of Cardiovascular/Thoracic Surgery at the University of Texas-Houston and Memorial Hermann-Texas Medical Center, and Surgical Director of Lung Transplantation. He received his undergraduate education (BS, Chemistry) at the University of Pittsburgh, followed by his MD and PhD (Immunology; laboratory of Jeffrey Bluestone) in the Medical Scientist Training Program at The University of Chicago. He undertook training in general surgery, part of which included a 2 year postdoctoral fellowship studying cardiovascular G protein coupled receptor signal transduction with Robert Lefkowitz, at Duke University Medical Center. Subsequently, he trained in cardiothoracic surgery at Duke. Currently, his clinical practice is the surgical management of end-stage heart and lung disease, while his scientific research efforts are focused on studying cardiac mechanotransduction and cardiovascular bioengineering.


OTHER REPRESENTATIVES:

SENIOR ADVISORS:

Doris A. Taylor, PhD
University of Minnesota
Minneapolis, Minnesota, USA

Doris A. Taylor, PhD, FAHA, FACC, is Founder, President, and CEO of Stem Cell Security, a cell banking and data management company in Houston, Texas. A pioneer in cardiovascular cell therapy and regenerative medicine research, Dr. Taylor has committed her entire career to moving innovative therapies from bench to bedside. Her mechanistic insights and effective approaches to cardiac repair and replacement are well established and include a number of firsts. She holds several invention disclosures, patent applications, and patents, and is the founder of multiple companies dedicated to cardiovascular repair technologies. She has published extensively, authoring or co-authoring more than 125 scientific publications, and holds many honors, including appointments as a Fellow of the American Heart Association, the American College of Cardiology, and the Council on Functional Genomics and Translational Biology, among others. She has been recognized by the AHA for Top 10 Research Advances and was awarded an honorary Doctorate Science degree by her alma mater, Mississippi University for Women in 2015. Dr. Taylor appears frequently as an expert on stem cell therapy and cardiac repair in the media as well as in the scientific arena. Her work has been recognized and featured by 60 Minutes, CNN, The New York Times, The Wall Street Journal, BBC News Health, the Associated Press, National Public Radio, and numerous other worldwide media outlets. She holds a B.S. from Mississippi University for Women in Biology and Physical Sciences in 1977 and a PhD in Pharmacology from the University of Texas Southwestern Medical Center, Dallas, Texas in 1987.


Jeffrey L. Platt, MD
University of Michigan
Ann Arbor, Michigan, USA

Jeffrey L. Platt, M.D. directs the Transplantation Biology Program and serves as Professor of Surgery, and Professor of Microbiology and Immunology at the University of Michigan.  He investigates how T cells and B cells and their products interact with tissues to cause disease and to induce protection against further injury, how novel approaches might be used to replace organ function and restore immunological fitness and how fusion of one cell with another impacts on genomic integrity and cellular function.  Dr. Platt is trained in Pediatrics (Childrens Hospital of LA) and nephrology (Univ Minnesota) and is a member of long standing of the ASN, AHA, the Association of American Physicians, IOM and the ISHLT.


ISHLT LINKS NEWSLETTER LIAISON:

Howard J. Eisen, MD, FAHA, FACC, FACP (2020)
Drexel University College of Medicine and Hahnemann University Hospital
Philadelphia, PA, USA

LIAISONS TO OTHER COUNCILS:

HFTX COUNCIL LIAISON:

Pradeep P.A. Mammen, MD, FACC, FAHA (2020)
UT Southwestern Medical Center
Dallas, Texas, USA

Bio coming soon...

ID COUNCIL LIAISON:

Orla Morrissey, MD (2020)
Alfred Health
Melbourne, AUSTRALIA

Bio coming soon...

JUNIOR FACULTY & TRAINEE COUNCIL LIAISON:

Simon Pecha, MD (2019)
University Hospital Hamburg
Hamburg, GERMANY

Simon Pecha, MD, is a Cardiac Surgeon at University Heart Center Hamburg, Germany and leads a Research group for Myocardial Tissue Engineering at Cardiovascular Research Center Hamburg. He obtained his MD from University of Tuebingen and received his training in Cardiovascular Surgery at University Heart Center Hamburg. His research is related to Cardiac Regeneration with a focus on Myocardial tissue engineering from human induced pluripotent stem cells. Dr. Pecha received several awards for his research including the Philip K. Caves Award in 2015 from the ISHLT and the Dr. Martini Price 2017 from the Dr. Martini Foundation.


MCS COUNCIL LIAISON:

J. Michael DiMaio, MD (2020)
Baylor University Medical Center
Dallas, TX, USA

Bio coming soon...

NHSAH COUNCIL LIAISON:

Monica Horn, RN, CCRN, CCTC (2020)
Children’s Hospital Los Angeles
Los Angeles, CA, USA

Monica Horn is a Heart Transplant/VAD/PH Coordinator II, Lead at Children’s Hospital Los Angeles. Previously a pediatric critical care RN, she became a cardiothoracic transplant coordinator in 1994, working with lung/heart-lung/lobar lung transplant,  heart transplant, pulmonary hypertension and ventricular assist device patients while participating in multiple research publications regarding these populations throughout this time. Recent interests have included multidisciplinary collaboration in care of pediatric ventricular assist device patients and patients referred for heart transplantation who have had multiple previous palliative congenital heart surgeries.



PATH COUNCIL LIAISON:

Annalisa Angelini, MD (2020)
University of Padua
Padova, ITALY

Bio coming soon...


PH COUNCIL LIAISON:

Aaron B Waxman, MD, PhD (2020)
Brigham & Women's Hospital
Boston, MA, USA

Bio coming soon...


PULM TX COUNCIL LIAISON:

Pablo G. Sanchez, MD, PhD (2020)
University of Pittsburgh
Pittsburgh, PA, USA

Pablo G Sanchez, MD PhD, is a Lung Transplant Surgeon. He is the  Associate Director of Lung Transplant and the Adult ECLS program and the Director of Ex vivo Lung Perfusion and Lung Transplant Research at the University of Pittsbugh. He obtained his MD from the University of Cordoba, Argentina in 1999. Residency and Thoracic Surgery fellowship was obtained at the Santa Casa de Misericordia, Porto Alegre, Brazil. He also completed a research fellowship at the University of Pennsylvania, and a Post Doc fellowship at the University of Maryland. He is a national co-investigator for the NOVEL trial, evaluating the use of ex vivo perfusion to increase lung donor use. He received the F. Griffith Pearson Fellowship from The American Association for Thoracic Surgery. He has also received funding from the Maryland Stem Cell Research Foundation, the ISHLT research fellowship award and the University of Maryland and Living Legacy Foundation Transplantation Grant Program Award.


Text SizeIncrease Font SizeDecrease Font Size